Idorsia (OTCMKTS:IDRSF – Get Free Report) will likely be releasing its resultson Thursday, July 30th. Analysts expect the company to announce earnings of ($0.2412) per share and revenue of $61.2360 million for the quarter.
Idorsia Stock Down 2.3%
IDRSF opened at $8.00 on Wednesday. The company has a fifty day moving average of $6.84 and a 200 day moving average of $5.37. Idorsia has a fifty-two week low of $3.30 and a fifty-two week high of $8.19.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Idorsia in a report on Monday, June 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.
Idorsia Company Profile
Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.
Read More
- Five stocks we like better than Idorsia
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
